1. Diagnostic criteria: One of the core indicators for diagnosing IDH wild-type GBM according to the WHO.2. Prognostic assessment: A strong poor prognostic factor is used to identify the most aggressive tumor types. This evidence concerns the gene IDH1 and glioblastoma.